122 related articles for article (PubMed ID: 24641516)
21. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
23. CNS metastases in breast cancer patients: prognostic implications of tumor subtype.
Bachmann C; Schmidt S; Staebler A; Fehm T; Fend F; Schittenhelm J; Wallwiener D; Grischke E
Med Oncol; 2015 Jan; 32(1):400. PubMed ID: 25433950
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients.
Langer I; Guller U; Worni M; Berclaz G; Singer G; Schaer G; Fehr MK; Hess T; Viehl C; Bronz L; Schnarwyler B; Wight E; Infanger E; Burger D; Koechli OR; Zuber M;
Ann Surg Oncol; 2014 Feb; 21(2):401-7. PubMed ID: 24145993
[TBL] [Abstract][Full Text] [Related]
25. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
26. A long-term survival pattern for breast cancer treated in a single institution.
Gokce T; Karadogan I; Akcay C
Indian J Cancer; 2011; 48(2):187-93. PubMed ID: 21768664
[TBL] [Abstract][Full Text] [Related]
27. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer.
Nguyen TL; Grizzle WE; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2013 Oct; 140(4):468-74. PubMed ID: 24045542
[TBL] [Abstract][Full Text] [Related]
28. Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution.
Cortadellas T; Córdoba O; Gascón A; Haladjian C; Bernabeu A; Alcalde A; Esgueva A; Rodriguez-Revuelto R; Espinosa-Bravo M; Díaz-Botero S; Xercavins J; Rubio IT; Gil-Moreno A
Eur J Surg Oncol; 2015 May; 41(5):635-40. PubMed ID: 25703077
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
[TBL] [Abstract][Full Text] [Related]
30. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base.
Greif JM; Pezzi CM; Klimberg VS; Bailey L; Zuraek M
Ann Surg Oncol; 2012 Oct; 19(10):3199-204. PubMed ID: 22766989
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
32. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
33. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.
Vo TN; Meric-Bernstam F; Yi M; Buchholz TA; Ames FC; Kuerer HM; Bedrosian I; Hunt KK
Am J Surg; 2006 Oct; 192(4):552-5. PubMed ID: 16978974
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study.
Rakha EA; Tan PH; Varga Z; Tse GM; Shaaban AM; Climent F; van Deurzen CH; Purnell D; Dodwell D; Chan T; Ellis IO
Br J Cancer; 2015 Jan; 112(2):283-9. PubMed ID: 25422911
[TBL] [Abstract][Full Text] [Related]
36. Nottingham grades of lobular carcinoma lack the prognostic implications they bear for ductal carcinoma.
Wachtel MS; Halldorsson A; Dissanaike S
J Surg Res; 2011 Mar; 166(1):19-27. PubMed ID: 20828724
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
38. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
[TBL] [Abstract][Full Text] [Related]
39. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
40. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
